Verastem to Present Initial VS-7375 Efficacy Data Across Three Cancer Types on Oct 14
VSTM has more than doubled off its 52-week low of $3.43.
Summary
Verastem will host an investor event on October 14 to present initial efficacy and updated safety data for VS-7375, its oral KRAS G12D inhibitor, across pancreatic, lung, and colorectal cancers. This builds on the June 2026 preliminary data and provides the first broader assessment across these tumor types. The company is running three registration-directed Phase 2 trials, and VS-7375 has FDA Fast Track Designation in pancreatic and lung cancers. The upcoming presentation could validate the drug's best-in-class potential and de-risk the pipeline. Investors will watch for efficacy signals in first-line pancreatic and lung settings, where the market opportunity is largest.
At the time of this announcement, VSTM was trading at $8.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $742.6M. The 52-week trading range was $3.43 to $11.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.